LUCA Science operates on the frontier of a novel branch of mitochondrial therapeutics applying its proprietary production technologies to various mitochondria related disease. Its mitochondrial transfer therapy restores function and biogenesis of cells with damaged or dysfunctional mitochondria as well as augments function of healthy cells.
Location: Japan, Chuo
Total raised: $30.3M
Investors 2
| Date | Name | Website |
| - | Fast Track... | us.fasttra... |
| - | J-Startup | j-startup.... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 08.06.2022 | Series B | $30.3M | 4BIO Capit... |
Mentions in press and media 6
| Date | Title | Description | Source |
| 10.06.2022 | Aiming to harness the power of mitochondria, a Japane... | One of the basic lessons in science class is that mitochondria act as the powerhouse of the c... | endpts.com... |
| 06.06.2022 | 4BIO Capital co-leads $30.3 million (¥3.86 Billion) oversubs... | Press Release 4BIO Capital co-leads $30.3 million (¥3.86 Billion) oversubscribed Series B financing... | globenewsw... |
| 06.06.2022 | 4BIO Capital co-leads $30 million (¥3.86 Billion) oversubscr... | - Financing reflects the potential of mitochondrial therapy to restore cellular bioenergetics in dys... | 4biocapita... |
| 03.09.2020 | Axil Capital leads $9.8m funding in Japanese biopharma Luca ... | Premium Tokyo-based venture capital firm Axil Capital has led a $9.8-million Series A funding in Lu... | dealstreet... |
| 01.09.2020 | Luca Science Raises $M in Series A Financing | Luca Science, a Tokyo, Japan-based company developing functional mitochondria as therapeutic agents,... | finsmes.co... |
| - | 4BIO Capital co-leads $30 million (¥3.86 Billion) oversubscr... | - Financing reflects the potential of mitochondrial therapy to restore cellular bioenergetics in dys... | 4biocapita... |